Keeps Biopharma Inc. (KOSDAQ:256940)

Keeps Biopharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	33,370	18,777	4,106	23,625	37,197	31,148
Short-Term Investments	2,718	3,934	756.56	30	3,092	35
Trading Asset Securities	3,469	276.08	6,047	1,549	600.6	519.47
Cash & Short-Term Investments	39,557	22,988	10,910	25,203	40,889	31,702
Cash Growth	37.69%	110.71%	-56.71%	-38.36%	28.98%	161.00%
Accounts Receivable	17,519	16,256	9,677	6,194	6,718	4,543
Other Receivables	422.3	460.57	1,925	212.39	332.01	300.87
Receivables	17,941	16,716	13,246	6,407	12,850	7,844
Inventory	26,942	20,436	5,328	1,602	2,246	273.82
Prepaid Expenses	403.56	828.01	113.06	53.6	42.96	30.35
Other Current Assets	26,143	9,746	17,169	10,044	7,315	10,227
Total Current Assets	110,986	70,714	46,766	43,310	63,342	50,077
Property, Plant & Equipment	38,741	35,068	28,376	10,062	10,365	10,834
Long-Term Investments	12,007	15,110	9,216	18,369	16,906	13,235
Goodwill	-	33,300	23,970	-	-	-
Other Intangible Assets	47,142	5,686	6,596	958.46	965.41	974.92
Long-Term Accounts Receivable	-	-0	0	129.69	361.77	518.99
Long-Term Deferred Tax Assets	252.92	312.11	1,528	-	-	-
Other Long-Term Assets	2,855	5,021	826.23	6,367	1,462	1,352
Total Assets	213,641	165,211	117,279	85,559	93,401	76,992
Accounts Payable	3,457	5,925	2,765	630.13	768.35	156.85
Accrued Expenses	2,061	1,969	1,956	744.98	901.09	854.94
Short-Term Debt	30,973	41,640	47,904	28,124	26,755	19,797
Current Portion of Long-Term Debt	159.67	330.72	-	-	-	-
Current Portion of Leases	222.49	276.49	308.59	310.16	276.52	258.63
Current Income Taxes Payable	223.18	2,991	-	-	-	-
Other Current Liabilities	34,491	32,295	2,946	2,250	1,496	838.84
Total Current Liabilities	71,587	85,427	55,880	32,059	30,197	21,906
Long-Term Debt	39,752	13,427	-	-	-	-
Long-Term Leases	114.09	62.85	91.93	386.34	571.69	682.4
Pension & Post-Retirement Benefits	357.4	424.77	525.41	-	-	-
Long-Term Deferred Tax Liabilities	2,452	1,308	356.28	248.32	766.68	2,656
Other Long-Term Liabilities	9,431	1,340	1,846	597.55	978.75	815.33
Total Liabilities	123,694	101,990	58,699	33,291	32,514	26,060
Common Stock	10,039	9,374	9,374	9,374	9,268	7,670
Additional Paid-In Capital	62,415	36,806	67,866	67,691	64,242	41,983
Retained Earnings	6,294	7,270	-23,631	-27,455	-15,188	129.71
Comprehensive Income & Other	-3,129	-3,317	3,627	3,462	2,704	375.31
Total Common Equity	75,619	50,134	57,236	53,072	61,026	50,158
Minority Interest	14,328	13,087	1,343	-804.49	-139.37	773.8
Shareholders' Equity	89,947	63,221	58,579	52,268	60,887	50,932
Total Liabilities & Equity	213,641	165,211	117,279	85,559	93,401	76,992
Total Debt	71,222	55,737	48,304	28,820	27,603	20,738
Net Cash (Debt)	-31,665	-32,749	-37,395	-3,617	13,286	10,964
Net Cash Growth	-	-	-	-	21.17%	67.40%
Net Cash Per Share	-1650.70	-1734.17	-1987.66	-193.02	767.26	748.58
Filing Date Shares Outstanding	20.08	18.75	18.75	18.75	18.54	15.34
Total Common Shares Outstanding	20.08	18.75	18.75	18.75	18.54	15.34
Working Capital	39,399	-14,713	-9,114	11,251	33,145	28,171
Book Value Per Share	3766.22	2673.99	3052.82	2830.71	3292.31	3269.86
Tangible Book Value	28,477	11,148	26,671	52,114	60,061	49,183
Tangible Book Value Per Share	1418.32	594.60	1422.53	2779.59	3240.22	3206.30
Land	-	13,663	12,710	3,022	3,022	3,022
Buildings	-	16,943	16,190	6,953	6,953	6,953
Machinery	-	20,991	15,312	3,343	3,283	3,191
Construction In Progress	-	2,886	-	-	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.